Skip to main content
Clinical Trials/NCT04251377
NCT04251377
Recruiting
Not Applicable

Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection SINBIOSE-H.

Centre Hospitalier Universitaire de Saint Etienne14 sites in 1 country440 target enrollmentSeptember 30, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hip Prosthesis Infection
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Enrollment
440
Locations
14
Primary Endpoint
Recurrence of clinically diagnosed infection relapse of the periprosthetic joint
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Each year, around 1500 infected Total Hip Arthroplasties (THA) need non-conservative surgery, remaining an issue for patients and healthcare units. The recommended treatment, relying on cohort reviews and international consensus follows a two-stage protocol. This protocol implies a first surgery to remove all infected implants and at least 6 weeks of antibiotic treatment without implant, then usually an antibiotic-free period and only then a second surgery to put back new implants and start the rehabilitation protocol, with usually more than a week of a second hospital stay. Between both surgeries, full-weight bearing is prohibited and joint stiffness and/or pain are rather usual complications. Failure rate is estimated at 10% in this two-stage strategy. The single-stage procedure (i.e. implanting back a new prosthesis during the same surgery after implant removal, synovectomy and lavage) is thought to be less susceptible to late functional complications (i.e. pain, stiffness and muscle deficiency) with a shorter, single hospital stay.

Although, with single-stage surgery, infection control could be less efficient because most pathogens produce during the first hours of infection an antibiotic-resistant layer called biofilm, allowing them to colonize and adhere to foreign objects like implants. This single-surgery protocol thus highly relies on antibiotics and has a list of contra-indications (based on experts' consensus): the presence of damaged soft tissues or a sinus tract, unknown pathogens, difficult to treat micro-organisms, severe immunosuppression and for many surgeons, each time a bone graft is necessary. Most of these contra-indications are directly related to the biofilm.

As no randomized control trial has ever compared single-stage versus two-stage surgery, the level of evidence for recommending one procedure over the other is low.

We conducted a survey that showed that most of the French reference centers have already switched to single stage surgery for single-stage non contra-indicated cases.

An antibiotic-loaded hydrogel coating (Defensive Antiadhesive Coating®, Novagenit SRL), has been proven to mechanically prevent the biofilm formation, while allowing a prolonged intraarticular antibiotic release, in a randomized controlled trial in primary prevention of infection in THA.

The addition of this biofilm inhibitor to a single-stage surgery might stand as a promising strategy for secondary prevention of peri-prosthetic hip joint infection. Moreover, using this device to prevent biofilm formation could expand one stage surgery to patients that are "normally" contra-indicated to one stage surgery.

Registry
clinicaltrials.gov
Start Date
September 30, 2021
End Date
December 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Social security affiliation
  • Signed informed consent
  • Chronic periprosthetic hip joint infection defined according to the Musculoskeletal Infection Society criteria :
  • Two positive periprosthetic cultures with phenotypically identical organisms
  • or a sinus tract communicating with the joint,
  • or having 3 of 5 minor criteria:
  • Elevated serum C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR);
  • Elevated synovial fluid White Blood Cell (WBC) count or change of ++ on leukocyte esterase test strip;
  • Elevated synovial fluid Polymorphonuclear Neutrophil Percentage (PMN%);
  • Positive histological analysis of periprosthetic tissue;

Exclusion Criteria

  • Patients with hypersensitivity to hydrogel components (hyaluronic acid and/or poly-lactic acid) known of Defensive Antibacterial Coating (DAC)®
  • Pregnancy or positive pregnancy test (performed in women of childbearing age before inclusion)
  • Life expectancy \< 3 months
  • Expected use of a cemented implant by the surgical team (for the treatment surgical protocol)
  • Unable to give informed consent
  • Patients under guardianship or curators
  • Refusal to participate

Outcomes

Primary Outcomes

Recurrence of clinically diagnosed infection relapse of the periprosthetic joint

Time Frame: Years : 2

The periprosthetic joint infection is defined according to the Musculoskeletal Infection Society criteria: * Two positive periprosthetic cultures with phenotypically identical organisms * or a sinus tract communicating with the joint, * or having 3 of 5 minor criteria: * Elevated serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR); * Elevated synovial fluid white blood cell (WBC) count; * Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%); * Positive histological analysis of periprosthetic tissue; * A single positive culture.

Secondary Outcomes

  • Hip dysfunction and Osteoarthritis Outcome Score (HOOS) results(Years : 2)
  • Revision surgery for any cause other than infection(Years : 2)
  • Post-operative complications(Years : 2)
  • Postel-Merle d'Aubigné (PMA) results(Years : 2)
  • Harris Hip Score (HHS) results(Years : 2)
  • Oxford-12 results(Years : 2)
  • Death rate (%)(Years : 2)

Study Sites (14)

Loading locations...

Similar Trials